Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EDIT 
Editas Medicine Inc (EDIT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: EDIT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $3.38
1 Year Target Price $3.38
| 4 | Strong Buy |
| 1 | Buy |
| 8 | Hold |
| 2 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 5.96% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 237.74M USD | Price to earnings Ratio - | 1Y Target Price 3.38 |
Price to earnings Ratio - | 1Y Target Price 3.38 | ||
Volume (30-day avg) 15 | Beta 2.1 | 52 Weeks Range 0.91 - 5.85 | Updated Date 07/17/2025 |
52 Weeks Range 0.91 - 5.85 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -758.05% |
Management Effectiveness
Return on Assets (TTM) -36.8% | Return on Equity (TTM) -140.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 48750648 | Price to Sales(TTM) 6.63 |
Enterprise Value 48750648 | Price to Sales(TTM) 6.63 | ||
Enterprise Value to Revenue 1.36 | Enterprise Value to EBITDA -1.36 | Shares Outstanding 83712896 | Shares Floating 83382193 |
Shares Outstanding 83712896 | Shares Floating 83382193 | ||
Percent Insiders 0.33 | Percent Institutions 57.56 |
Upturn AI SWOT
Editas Medicine Inc
Company Overview
History and Background
Editas Medicine Inc. was founded in 2013. It focuses on developing CRISPR-based gene editing therapies. Key milestones include preclinical validation of its technology and advancing programs into clinical trials.
Core Business Areas
- Genome Editing Therapies: Development and commercialization of CRISPR-based therapies for various genetic diseases. Focus on in vivo and ex vivo gene editing.
- Research and Development: Ongoing research to improve CRISPR technology and expand its applications to new disease targets.
Leadership and Structure
The leadership team includes the CEO, Chief Scientific Officer, and Chief Medical Officer. The organizational structure consists of research, development, and commercial operations departments.
Top Products and Market Share
Key Offerings
- EDIT-101: EDIT-101 is an in vivo CRISPR-based medicine under development for the treatment of Leber congenital amaurosis 10 (LCA10). EDIT-101 is Editas Medicine's most advanced clinical program. Competitors include companies developing gene therapies for inherited retinal diseases, such as ProQR Therapeutics (failed late stage trail) and REGENXBIO (RGNX). Market share for EDIT-101 cannot be specified due to being in clinical trials and is not generating revenue yet.
- EDIT-301: EDIT-301 is an investigational ex vivo gene-editing therapy in development for the treatment of severe sickle cell disease. Competing companies in the sickle cell disease gene therapy space include Vertex Pharmaceuticals (CRSP) (partnered with CRISPR Therapeutics) and bluebird bio (BLUE). EDIT-301 is currently in clinical trials and is not generating revenue yet; market share is not available
Market Dynamics
Industry Overview
The gene editing industry is rapidly growing, driven by advances in CRISPR technology and increasing demand for treatments for genetic diseases.
Positioning
Editas Medicine Inc. is a leading company in the gene editing space, with a focus on CRISPR-based therapies. Its competitive advantage lies in its early-stage technology and scientific expertise.
Total Addressable Market (TAM)
The TAM for gene editing is projected to reach billions of dollars in the coming years. Editas is positioned to capture a share of this market through the development of novel therapies.
Upturn SWOT Analysis
Strengths
- Strong CRISPR technology platform
- Experienced management team
- Early mover advantage
- Robust intellectual property portfolio
Weaknesses
- Clinical trial risks
- High research and development costs
- Dependence on CRISPR technology
- Regulatory hurdles
Opportunities
- Expansion into new disease areas
- Partnerships with pharmaceutical companies
- Advancement of clinical programs
- Increasing market demand for gene editing therapies
Threats
- Competition from other gene editing companies
- Adverse clinical trial results
- Regulatory challenges
- Ethical concerns about gene editing
Competitors and Market Share
Key Competitors
- CRSP
- BLUE
- RGNX
Competitive Landscape
Editas Medicine Inc. faces competition from other gene editing companies. Advantages include early stage technology and expert team. Disadvantages include competition and clinical trial risks. Market Share estimated to represent future market share when products are commercialized and not based on current earnings.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancement of CRISPR technology and strategic partnerships.
Future Projections: Future growth is projected to come from successful clinical trials and commercialization of gene editing therapies.
Recent Initiatives: Recent initiatives include advancing EDIT-101 and EDIT-301 through clinical trials and expanding collaborations.
Summary
Editas Medicine Inc. is a gene editing company focused on CRISPR-based therapies. It has a strong technology platform and experienced team, but faces clinical trial risks and competition. Editas is working to advance its clinical programs and expand its pipeline. The company needs to be mindful of competition, clinical trial outcomes, and regulatory challenges to make up its future plans.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share information is estimated based on industry analysis and company positioning. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Editas Medicine Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2016-02-03 | President, CEO & Director Dr. Gilmore O'Neill M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 246 | Website https://www.editasmedicine.com |
Full time employees 246 | Website https://www.editasmedicine.com | ||
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.